Tianjin Tianyao Pharmaceuticals Denies Acquisition By Pfizer
This article was originally published in PharmAsia News
Tianjin Tianyao Pharmaceuticals, a dominant steroid manufacturer in China, has denied reports that it is in discussion with Pfizer for acquisition (PharmAsia News Jun. 23, 2008). According to company insiders, Tianyao and Pfizer have been collaborating for several years, and Tianyao is a raw material supplier for the pharmaceutical giant which monopolizes the steroid hormone market in China. To date, both parties' partnership has not changed, with Tianyao still a Pfizer's vendor. (Click here for more - Chinese Language)
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.